Grey Matter Pharma

Grey Matter Pharma is a specialty pharmaceutical company focused on the development and commercialization of value-added medicines through drug repurposing and advanced formulation technologies. The company's lead program, GM-28K, is a novel oral capsule formulation of esketamine hydrochloride currently in Phase 1 clinical trials for the treatment of treatment-resistant depression (TRD). Grey Matter Pharma aims to provide more accessible and convenient alternatives to existing intranasal and intravenous therapies for mental health and CNS disorders. The company operates globally with entities in the UK, Australia, and Singapore, and is led by experienced pharmaceutical executives with backgrounds in specialty pharma and drug delivery.